nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadobenate Dimeglumine—ALB—liver cancer	0.78	1	CbGaD
Gadobenate Dimeglumine—Infection—Sorafenib—liver cancer	0.00057	0.00259	CcSEcCtD
Gadobenate Dimeglumine—Inflammation—Doxorubicin—liver cancer	0.000567	0.00257	CcSEcCtD
Gadobenate Dimeglumine—Shock—Sorafenib—liver cancer	0.000564	0.00256	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Sorafenib—liver cancer	0.000562	0.00255	CcSEcCtD
Gadobenate Dimeglumine—Blood urea increased—Epirubicin—liver cancer	0.000561	0.00255	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Sorafenib—liver cancer	0.000557	0.00253	CcSEcCtD
Gadobenate Dimeglumine—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.00055	0.00249	CcSEcCtD
Gadobenate Dimeglumine—Pulmonary embolism—Doxorubicin—liver cancer	0.00055	0.00249	CcSEcCtD
Gadobenate Dimeglumine—Injection site reaction—Doxorubicin—liver cancer	0.000546	0.00248	CcSEcCtD
Gadobenate Dimeglumine—Cramps of lower extremities—Epirubicin—liver cancer	0.000546	0.00248	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis contact—Doxorubicin—liver cancer	0.000543	0.00247	CcSEcCtD
Gadobenate Dimeglumine—Hyperkalaemia—Doxorubicin—liver cancer	0.00054	0.00245	CcSEcCtD
Gadobenate Dimeglumine—Rash maculo-papular—Epirubicin—liver cancer	0.00054	0.00245	CcSEcCtD
Gadobenate Dimeglumine—Ecchymosis—Epirubicin—liver cancer	0.000537	0.00244	CcSEcCtD
Gadobenate Dimeglumine—Salivary hypersecretion—Doxorubicin—liver cancer	0.000534	0.00242	CcSEcCtD
Gadobenate Dimeglumine—Pulmonary oedema—Epirubicin—liver cancer	0.000529	0.0024	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000523	0.00237	CcSEcCtD
Gadobenate Dimeglumine—Hypertonia—Epirubicin—liver cancer	0.000521	0.00236	CcSEcCtD
Gadobenate Dimeglumine—Blood urea increased—Doxorubicin—liver cancer	0.000519	0.00235	CcSEcCtD
Gadobenate Dimeglumine—Abnormal vision—Epirubicin—liver cancer	0.000518	0.00235	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Sorafenib—liver cancer	0.000511	0.00232	CcSEcCtD
Gadobenate Dimeglumine—Cramps of lower extremities—Doxorubicin—liver cancer	0.000505	0.00229	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Sorafenib—liver cancer	0.000505	0.00229	CcSEcCtD
Gadobenate Dimeglumine—Phlebitis—Epirubicin—liver cancer	0.000501	0.00227	CcSEcCtD
Gadobenate Dimeglumine—Rash maculo-papular—Doxorubicin—liver cancer	0.0005	0.00227	CcSEcCtD
Gadobenate Dimeglumine—Ecchymosis—Doxorubicin—liver cancer	0.000497	0.00226	CcSEcCtD
Gadobenate Dimeglumine—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000496	0.00225	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Sorafenib—liver cancer	0.000495	0.00225	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Sorafenib—liver cancer	0.000494	0.00224	CcSEcCtD
Gadobenate Dimeglumine—Hepatic function abnormal—Epirubicin—liver cancer	0.000493	0.00224	CcSEcCtD
Gadobenate Dimeglumine—Pain—Sorafenib—liver cancer	0.00049	0.00223	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Sorafenib—liver cancer	0.00049	0.00223	CcSEcCtD
Gadobenate Dimeglumine—Pulmonary oedema—Doxorubicin—liver cancer	0.000489	0.00222	CcSEcCtD
Gadobenate Dimeglumine—Hypertonia—Doxorubicin—liver cancer	0.000482	0.00219	CcSEcCtD
Gadobenate Dimeglumine—Abnormal vision—Doxorubicin—liver cancer	0.000479	0.00218	CcSEcCtD
Gadobenate Dimeglumine—Eye pain—Epirubicin—liver cancer	0.000478	0.00217	CcSEcCtD
Gadobenate Dimeglumine—Cardiac failure congestive—Epirubicin—liver cancer	0.000476	0.00216	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Sorafenib—liver cancer	0.000469	0.00213	CcSEcCtD
Gadobenate Dimeglumine—Phlebitis—Doxorubicin—liver cancer	0.000463	0.0021	CcSEcCtD
Gadobenate Dimeglumine—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000459	0.00208	CcSEcCtD
Gadobenate Dimeglumine—Hepatic function abnormal—Doxorubicin—liver cancer	0.000457	0.00207	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Sorafenib—liver cancer	0.000456	0.00207	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Sorafenib—liver cancer	0.000453	0.00206	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Sorafenib—liver cancer	0.000453	0.00206	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis bullous—Epirubicin—liver cancer	0.000451	0.00205	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactoid reaction—Epirubicin—liver cancer	0.000446	0.00202	CcSEcCtD
Gadobenate Dimeglumine—Eye pain—Doxorubicin—liver cancer	0.000442	0.00201	CcSEcCtD
Gadobenate Dimeglumine—Hypoglycaemia—Epirubicin—liver cancer	0.000442	0.00201	CcSEcCtD
Gadobenate Dimeglumine—Cardiac failure—Epirubicin—liver cancer	0.000442	0.00201	CcSEcCtD
Gadobenate Dimeglumine—Cardiac failure congestive—Doxorubicin—liver cancer	0.00044	0.002	CcSEcCtD
Gadobenate Dimeglumine—Hyponatraemia—Epirubicin—liver cancer	0.000433	0.00196	CcSEcCtD
Gadobenate Dimeglumine—Pain in extremity—Epirubicin—liver cancer	0.000431	0.00196	CcSEcCtD
Gadobenate Dimeglumine—Migraine—Epirubicin—liver cancer	0.000425	0.00193	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Sorafenib—liver cancer	0.000423	0.00192	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis bullous—Doxorubicin—liver cancer	0.000418	0.00189	CcSEcCtD
Gadobenate Dimeglumine—Face oedema—Epirubicin—liver cancer	0.000416	0.00189	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000412	0.00187	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Sorafenib—liver cancer	0.000412	0.00187	CcSEcCtD
Gadobenate Dimeglumine—Cardiac arrest—Epirubicin—liver cancer	0.00041	0.00186	CcSEcCtD
Gadobenate Dimeglumine—Hypoglycaemia—Doxorubicin—liver cancer	0.000409	0.00186	CcSEcCtD
Gadobenate Dimeglumine—Cardiac failure—Doxorubicin—liver cancer	0.000409	0.00186	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Sorafenib—liver cancer	0.000406	0.00184	CcSEcCtD
Gadobenate Dimeglumine—Blood creatinine increased—Epirubicin—liver cancer	0.000404	0.00183	CcSEcCtD
Gadobenate Dimeglumine—Hyponatraemia—Doxorubicin—liver cancer	0.000401	0.00182	CcSEcCtD
Gadobenate Dimeglumine—Pain in extremity—Doxorubicin—liver cancer	0.000399	0.00181	CcSEcCtD
Gadobenate Dimeglumine—Liver function test abnormal—Epirubicin—liver cancer	0.000398	0.00181	CcSEcCtD
Gadobenate Dimeglumine—Migraine—Doxorubicin—liver cancer	0.000393	0.00178	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Sorafenib—liver cancer	0.000392	0.00178	CcSEcCtD
Gadobenate Dimeglumine—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000388	0.00176	CcSEcCtD
Gadobenate Dimeglumine—Nasopharyngitis—Epirubicin—liver cancer	0.000386	0.00175	CcSEcCtD
Gadobenate Dimeglumine—Face oedema—Doxorubicin—liver cancer	0.000385	0.00175	CcSEcCtD
Gadobenate Dimeglumine—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00038	0.00173	CcSEcCtD
Gadobenate Dimeglumine—Cardiac arrest—Doxorubicin—liver cancer	0.000379	0.00172	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Sorafenib—liver cancer	0.000379	0.00172	CcSEcCtD
Gadobenate Dimeglumine—Blood creatinine increased—Doxorubicin—liver cancer	0.000374	0.0017	CcSEcCtD
Gadobenate Dimeglumine—Asthma—Epirubicin—liver cancer	0.000373	0.00169	CcSEcCtD
Gadobenate Dimeglumine—Liver function test abnormal—Doxorubicin—liver cancer	0.000368	0.00167	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Sorafenib—liver cancer	0.000365	0.00165	CcSEcCtD
Gadobenate Dimeglumine—Rash—Sorafenib—liver cancer	0.000362	0.00164	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Sorafenib—liver cancer	0.000361	0.00164	CcSEcCtD
Gadobenate Dimeglumine—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000359	0.00163	CcSEcCtD
Gadobenate Dimeglumine—Headache—Sorafenib—liver cancer	0.000359	0.00163	CcSEcCtD
Gadobenate Dimeglumine—Bronchitis—Epirubicin—liver cancer	0.000358	0.00163	CcSEcCtD
Gadobenate Dimeglumine—Nasopharyngitis—Doxorubicin—liver cancer	0.000357	0.00162	CcSEcCtD
Gadobenate Dimeglumine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000352	0.0016	CcSEcCtD
Gadobenate Dimeglumine—Asthma—Doxorubicin—liver cancer	0.000345	0.00156	CcSEcCtD
Gadobenate Dimeglumine—Pollakiuria—Epirubicin—liver cancer	0.000344	0.00156	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Sorafenib—liver cancer	0.000341	0.00155	CcSEcCtD
Gadobenate Dimeglumine—Hyperglycaemia—Epirubicin—liver cancer	0.000336	0.00153	CcSEcCtD
Gadobenate Dimeglumine—Infestation—Epirubicin—liver cancer	0.000332	0.00151	CcSEcCtD
Gadobenate Dimeglumine—Infestation NOS—Epirubicin—liver cancer	0.000332	0.00151	CcSEcCtD
Gadobenate Dimeglumine—Bronchitis—Doxorubicin—liver cancer	0.000332	0.00151	CcSEcCtD
Gadobenate Dimeglumine—Renal failure—Epirubicin—liver cancer	0.000327	0.00148	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract infection—Epirubicin—liver cancer	0.000323	0.00147	CcSEcCtD
Gadobenate Dimeglumine—Conjunctivitis—Epirubicin—liver cancer	0.000323	0.00147	CcSEcCtD
Gadobenate Dimeglumine—Sweating—Epirubicin—liver cancer	0.000319	0.00145	CcSEcCtD
Gadobenate Dimeglumine—Pollakiuria—Doxorubicin—liver cancer	0.000319	0.00145	CcSEcCtD
Gadobenate Dimeglumine—Haematuria—Epirubicin—liver cancer	0.000317	0.00144	CcSEcCtD
Gadobenate Dimeglumine—Hyperglycaemia—Doxorubicin—liver cancer	0.000311	0.00141	CcSEcCtD
Gadobenate Dimeglumine—Infestation NOS—Doxorubicin—liver cancer	0.000308	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Infestation—Doxorubicin—liver cancer	0.000308	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Bradycardia—Epirubicin—liver cancer	0.000304	0.00138	CcSEcCtD
Gadobenate Dimeglumine—Renal failure—Doxorubicin—liver cancer	0.000302	0.00137	CcSEcCtD
Gadobenate Dimeglumine—Rhinitis—Epirubicin—liver cancer	0.000299	0.00136	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract infection—Doxorubicin—liver cancer	0.000299	0.00136	CcSEcCtD
Gadobenate Dimeglumine—Conjunctivitis—Doxorubicin—liver cancer	0.000299	0.00136	CcSEcCtD
Gadobenate Dimeglumine—Hypoaesthesia—Epirubicin—liver cancer	0.000297	0.00135	CcSEcCtD
Gadobenate Dimeglumine—Sweating—Doxorubicin—liver cancer	0.000295	0.00134	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Epirubicin—liver cancer	0.000295	0.00134	CcSEcCtD
Gadobenate Dimeglumine—Oedema peripheral—Epirubicin—liver cancer	0.000294	0.00133	CcSEcCtD
Gadobenate Dimeglumine—Haematuria—Doxorubicin—liver cancer	0.000293	0.00133	CcSEcCtD
Gadobenate Dimeglumine—Connective tissue disorder—Epirubicin—liver cancer	0.000293	0.00133	CcSEcCtD
Gadobenate Dimeglumine—Urethral disorder—Epirubicin—liver cancer	0.000292	0.00133	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Epirubicin—liver cancer	0.000288	0.0013	CcSEcCtD
Gadobenate Dimeglumine—Bradycardia—Doxorubicin—liver cancer	0.000281	0.00128	CcSEcCtD
Gadobenate Dimeglumine—Eye disorder—Epirubicin—liver cancer	0.000279	0.00127	CcSEcCtD
Gadobenate Dimeglumine—Tinnitus—Epirubicin—liver cancer	0.000278	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Flushing—Epirubicin—liver cancer	0.000277	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Epirubicin—liver cancer	0.000277	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Rhinitis—Doxorubicin—liver cancer	0.000277	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Hypoaesthesia—Doxorubicin—liver cancer	0.000275	0.00125	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Doxorubicin—liver cancer	0.000273	0.00124	CcSEcCtD
Gadobenate Dimeglumine—Oedema peripheral—Doxorubicin—liver cancer	0.000272	0.00123	CcSEcCtD
Gadobenate Dimeglumine—Connective tissue disorder—Doxorubicin—liver cancer	0.000271	0.00123	CcSEcCtD
Gadobenate Dimeglumine—Angiopathy—Epirubicin—liver cancer	0.000271	0.00123	CcSEcCtD
Gadobenate Dimeglumine—Urethral disorder—Doxorubicin—liver cancer	0.000271	0.00123	CcSEcCtD
Gadobenate Dimeglumine—Immune system disorder—Epirubicin—liver cancer	0.000269	0.00122	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Epirubicin—liver cancer	0.000269	0.00122	CcSEcCtD
Gadobenate Dimeglumine—Chills—Epirubicin—liver cancer	0.000268	0.00121	CcSEcCtD
Gadobenate Dimeglumine—Arrhythmia—Epirubicin—liver cancer	0.000267	0.00121	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Doxorubicin—liver cancer	0.000266	0.00121	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Epirubicin—liver cancer	0.000261	0.00119	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Epirubicin—liver cancer	0.00026	0.00118	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Epirubicin—liver cancer	0.00026	0.00118	CcSEcCtD
Gadobenate Dimeglumine—Eye disorder—Doxorubicin—liver cancer	0.000258	0.00117	CcSEcCtD
Gadobenate Dimeglumine—Tinnitus—Doxorubicin—liver cancer	0.000257	0.00117	CcSEcCtD
Gadobenate Dimeglumine—Flushing—Doxorubicin—liver cancer	0.000256	0.00116	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Doxorubicin—liver cancer	0.000256	0.00116	CcSEcCtD
Gadobenate Dimeglumine—Dysgeusia—Epirubicin—liver cancer	0.000254	0.00115	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Epirubicin—liver cancer	0.000251	0.00114	CcSEcCtD
Gadobenate Dimeglumine—Angiopathy—Doxorubicin—liver cancer	0.00025	0.00114	CcSEcCtD
Gadobenate Dimeglumine—Muscle spasms—Epirubicin—liver cancer	0.00025	0.00113	CcSEcCtD
Gadobenate Dimeglumine—Immune system disorder—Doxorubicin—liver cancer	0.000249	0.00113	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Doxorubicin—liver cancer	0.000249	0.00113	CcSEcCtD
Gadobenate Dimeglumine—Chills—Doxorubicin—liver cancer	0.000248	0.00112	CcSEcCtD
Gadobenate Dimeglumine—Arrhythmia—Doxorubicin—liver cancer	0.000247	0.00112	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Doxorubicin—liver cancer	0.000242	0.0011	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Epirubicin—liver cancer	0.000241	0.00109	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Doxorubicin—liver cancer	0.00024	0.00109	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Doxorubicin—liver cancer	0.00024	0.00109	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Epirubicin—liver cancer	0.00024	0.00109	CcSEcCtD
Gadobenate Dimeglumine—Dysgeusia—Doxorubicin—liver cancer	0.000235	0.00107	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Epirubicin—liver cancer	0.000234	0.00106	CcSEcCtD
Gadobenate Dimeglumine—Syncope—Epirubicin—liver cancer	0.000233	0.00106	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Epirubicin—liver cancer	0.000232	0.00105	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Doxorubicin—liver cancer	0.000232	0.00105	CcSEcCtD
Gadobenate Dimeglumine—Muscle spasms—Doxorubicin—liver cancer	0.000231	0.00105	CcSEcCtD
Gadobenate Dimeglumine—Palpitations—Epirubicin—liver cancer	0.00023	0.00104	CcSEcCtD
Gadobenate Dimeglumine—Loss of consciousness—Epirubicin—liver cancer	0.000228	0.00104	CcSEcCtD
Gadobenate Dimeglumine—Cough—Epirubicin—liver cancer	0.000227	0.00103	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Epirubicin—liver cancer	0.000224	0.00102	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Doxorubicin—liver cancer	0.000223	0.00101	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Doxorubicin—liver cancer	0.000222	0.00101	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Epirubicin—liver cancer	0.000221	0.001	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Epirubicin—liver cancer	0.000221	0.001	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Epirubicin—liver cancer	0.000221	0.001	CcSEcCtD
Gadobenate Dimeglumine—Anxiety—Epirubicin—liver cancer	0.00022	0.001	CcSEcCtD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00022	0.000996	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Epirubicin—liver cancer	0.000218	0.000991	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Doxorubicin—liver cancer	0.000217	0.000983	CcSEcCtD
Gadobenate Dimeglumine—Dry mouth—Epirubicin—liver cancer	0.000216	0.000981	CcSEcCtD
Gadobenate Dimeglumine—Syncope—Doxorubicin—liver cancer	0.000216	0.000978	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Doxorubicin—liver cancer	0.000215	0.000976	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Epirubicin—liver cancer	0.000214	0.00097	CcSEcCtD
Gadobenate Dimeglumine—Palpitations—Doxorubicin—liver cancer	0.000212	0.000964	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Epirubicin—liver cancer	0.000212	0.000962	CcSEcCtD
Gadobenate Dimeglumine—Loss of consciousness—Doxorubicin—liver cancer	0.000211	0.000958	CcSEcCtD
Gadobenate Dimeglumine—Infection—Epirubicin—liver cancer	0.000211	0.000956	CcSEcCtD
Gadobenate Dimeglumine—Cough—Doxorubicin—liver cancer	0.00021	0.000952	CcSEcCtD
Gadobenate Dimeglumine—Shock—Epirubicin—liver cancer	0.000209	0.000946	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Epirubicin—liver cancer	0.000208	0.000943	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Doxorubicin—liver cancer	0.000207	0.000941	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Epirubicin—liver cancer	0.000207	0.000939	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Epirubicin—liver cancer	0.000206	0.000934	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Epirubicin—liver cancer	0.000205	0.00093	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Doxorubicin—liver cancer	0.000205	0.000928	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Doxorubicin—liver cancer	0.000205	0.000928	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Doxorubicin—liver cancer	0.000205	0.000928	CcSEcCtD
Gadobenate Dimeglumine—Anxiety—Doxorubicin—liver cancer	0.000204	0.000925	CcSEcCtD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000203	0.000922	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Doxorubicin—liver cancer	0.000202	0.000917	CcSEcCtD
Gadobenate Dimeglumine—Dry mouth—Doxorubicin—liver cancer	0.0002	0.000908	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Epirubicin—liver cancer	0.000198	0.000899	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Doxorubicin—liver cancer	0.000198	0.000897	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Doxorubicin—liver cancer	0.000196	0.00089	CcSEcCtD
Gadobenate Dimeglumine—Infection—Doxorubicin—liver cancer	0.000195	0.000884	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000193	0.000876	CcSEcCtD
Gadobenate Dimeglumine—Shock—Doxorubicin—liver cancer	0.000193	0.000876	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Doxorubicin—liver cancer	0.000192	0.000873	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Doxorubicin—liver cancer	0.000191	0.000869	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Doxorubicin—liver cancer	0.000191	0.000864	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Epirubicin—liver cancer	0.00019	0.000864	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Doxorubicin—liver cancer	0.00019	0.00086	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Epirubicin—liver cancer	0.000189	0.000857	CcSEcCtD
Gadobenate Dimeglumine—Somnolence—Epirubicin—liver cancer	0.000188	0.000855	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Epirubicin—liver cancer	0.000187	0.000847	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Doxorubicin—liver cancer	0.000183	0.000832	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000183	0.00083	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Epirubicin—liver cancer	0.000183	0.000829	CcSEcCtD
Gadobenate Dimeglumine—Pain—Epirubicin—liver cancer	0.000181	0.000822	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Epirubicin—liver cancer	0.000181	0.000822	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000179	0.000811	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Doxorubicin—liver cancer	0.000176	0.000799	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Doxorubicin—liver cancer	0.000175	0.000793	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Epirubicin—liver cancer	0.000175	0.000793	CcSEcCtD
Gadobenate Dimeglumine—Somnolence—Doxorubicin—liver cancer	0.000174	0.000791	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Epirubicin—liver cancer	0.000173	0.000786	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Doxorubicin—liver cancer	0.000173	0.000783	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000169	0.000768	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Doxorubicin—liver cancer	0.000169	0.000767	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Epirubicin—liver cancer	0.000168	0.000764	CcSEcCtD
Gadobenate Dimeglumine—Pain—Doxorubicin—liver cancer	0.000168	0.000761	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Doxorubicin—liver cancer	0.000168	0.000761	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Epirubicin—liver cancer	0.000168	0.00076	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Epirubicin—liver cancer	0.000168	0.00076	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Doxorubicin—liver cancer	0.000162	0.000733	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Doxorubicin—liver cancer	0.00016	0.000728	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Epirubicin—liver cancer	0.000156	0.000709	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Doxorubicin—liver cancer	0.000156	0.000707	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Doxorubicin—liver cancer	0.000155	0.000704	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Doxorubicin—liver cancer	0.000155	0.000704	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Epirubicin—liver cancer	0.000152	0.00069	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Epirubicin—liver cancer	0.00015	0.00068	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Epirubicin—liver cancer	0.000145	0.000658	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Doxorubicin—liver cancer	0.000145	0.000656	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Doxorubicin—liver cancer	0.000141	0.000639	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Epirubicin—liver cancer	0.00014	0.000636	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Doxorubicin—liver cancer	0.000139	0.00063	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Epirubicin—liver cancer	0.000135	0.000612	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Doxorubicin—liver cancer	0.000134	0.000609	CcSEcCtD
Gadobenate Dimeglumine—Rash—Epirubicin—liver cancer	0.000134	0.000606	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Epirubicin—liver cancer	0.000134	0.000606	CcSEcCtD
Gadobenate Dimeglumine—Headache—Epirubicin—liver cancer	0.000133	0.000603	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Doxorubicin—liver cancer	0.00013	0.000588	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Epirubicin—liver cancer	0.000126	0.000571	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Doxorubicin—liver cancer	0.000125	0.000566	CcSEcCtD
Gadobenate Dimeglumine—Rash—Doxorubicin—liver cancer	0.000124	0.000561	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Doxorubicin—liver cancer	0.000124	0.000561	CcSEcCtD
Gadobenate Dimeglumine—Headache—Doxorubicin—liver cancer	0.000123	0.000558	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Doxorubicin—liver cancer	0.000116	0.000529	CcSEcCtD
